Pemphigoid and Pemphigus2
Pemphigoid and Pemphigus2
Pemphigoid and Pemphigus2
PEMPHIGOID
A number of other sub-epithelial vesicullobullous disorders may produce similar clinical features(table1)
● pemphigoid variants
● acquired epidermolysis bullosa (EBA)
● toxic epidermal necrolysis(TEN)
● Erythema multiforme
● Dermatitis herpetiforms
● linear IgA disease
● chronic bullous dermatosis of childhood
the main types of pemphigoid that involve the mouth are:
● mucous membrane pemphigoid(MMP) in which mucosal lesions predominate but skin lesions
are rare
● oral mucosal pemphigoid patients with oral lesions only without a progressive ocular scarring
process and without serologic reactivity to bullous pemphigoid (BP) antigens
● bullous pemphigoid (BP) which affects mainly the skin
● ocular pemphigoid which is sometimes termed cicatricial pemphigoid (CP) since it may cause
serous conjunctival scarring.
Mucous membrane/oral pemphigoid
The precipitating event is unclear in most cases but rare cases are drug induced(eg by furosemide or
penicillamine).
it is characterized immunologically by deposition of IgG and C3 antibosies directed against the epithelial
basement memrane zone(BMZ)
There are also circulating antibodies in BMZ components and desmosomes of the lamina ........?
the antibodies damage the BMZ and histollogically there is a sub-basilar split.
Clincal features
The oral lesions affect especially the gingivae and palate and include bullae or vesicles which are tense
may be blood filled and remain intact for several days
persistent irregular ulcers appear after the blisters rupture anf if on the gingivae can produce
desquamative gingivitis -the most common oral finding.
This is characterized by erythematous ulcerated tender gingiva in a patchy rather than continuous
distribution.
The majority of the people with MMP have only oral lesions but general involvement can cause great
morbidity and untreated ocular involvement can lead to blindness . Nasal laryngeal and skin blisters are
rare.
Diagnosis
the oral lesions of the pemphigoid may be confused clinically with pemphigus or occasionally erosive
lichen planus erythema multiforme or the subepithelial blistering conditions shown in table1
biopsy of prelesional tissue with histological and immunstaining examination can therefore be essential
to the diagnosis
Management
spontaneous remission is rare and thus treatment is indicated. Specialist advice is usually needed.
The majority of cases respond well to topical corticosteroids. Non-steroidal immunosupresive agents
may be needed if the response is inadequate.
PEMPHIGUS
There are several varients with different autoantibody profiles and clinical manifestations but the main
type is pemhigus vulgaris this includes an uncommon variant pemhigus vegetans.
pemphigus vulgaris is seen mainly in middle aged and elderly females of Mediterranean Arabs,
Ashkenazi jewish or south Asian descent.
Pemphigus vulgaris is an autoimmune disorder in which there is fairly srong genetic background.
Rare cases have been trigered by medications ( especially captopril, penicillamine, rifampine and
diclofenac) or other factors.
Damage to the Desmosomes leads to loss of cell-cell contact (acantholysis), and thus INTRA-EPITHELIAL
vesiculation.
Clinical features
pemphigus vulgaris typically runs to chronic course, causing blisters, erosions on the mucosa and blisters
and scabs on the skin.
Blisters rapidly breakdown to leave erosions seen mainly on the palate (soft palate and posterior hard
palate),buccal mucosa,lips and gingiva white lesions usually comprise severe desquamative or erosive
gingivitis, flaps of peeling tissue with red erosions or deep ulcerative craters are seen, mainly on the
attached gingiva)
Diagnosis
to differentiate pemphigus from other vesiculobullous diseases, a careful history and physical
examination are important, but biopsy of prelesional tissue, with histological and immunostaining
examination are crucial.
Management
Before the introduction of corticosteroids, pemphigus vulgaris typically was fatal, mainly from
dehydration or secondary systemic infections.
Current treatment, by systemic immunosupression, has significantly reduced the mortality to about
10%.